Kura Oncology Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
KURA$7.57+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Operating Activities | |||
| Net loss | $(173,983) | $(152,631) | $(135,840) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
| Share-based compensation expense | 33,897 | 28,082 | 26,318 |
| Amortization of premium and accretion of discounts on short-term investments, net | (13,141) | (9,420) | 1,610 |
| Depreciation expense | 848 | 849 | 759 |
| Non-cash interest expense | 523 | 477 | 73 |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | (8,910) | (1,960) | (2,935) |
| Contract liabilities | 278,178 | — | — |
| Accounts payable and accrued expenses | 15,200 | 10,327 | (802) |
| Operating lease right-of-use and other long-term assets | 947 | (685) | 571 |
| Other long-term liabilities | 758 | 137 | 184 |
| Net cash provided by (used in) operating activities | 134,317 | (124,824) | (110,062) |
| Investing Activities | |||
| Purchases of short-term investments | (659,048) | (409,824) | (270,655) |
| Maturities of short-term investments | 557,930 | 425,549 | 303,908 |
| Purchases of property and equipment | (472) | (168) | (626) |
| Net cash provided by (used in) investing activities | (101,590) | 15,557 | 32,627 |
| Financing Activities | |||
| Proceeds from issuances of common stock and pre-funded warrants, net of offering costs | 145,813 | 93,577 | 24,721 |
| Proceeds from issuance of stock under equity plans | 8,604 | 1,206 | 4,419 |
| Proceeds from long-term debt | — | — | 10,000 |
| Payment of fees related to issuance of long-term debt | — | — | (575) |
| Net cash provided by financing activities | 154,417 | 94,783 | 38,565 |
| Net increase (decrease) in cash and cash equivalents | 187,144 | (14,484) | (38,870) |
| Cash and cash equivalents at beginning of period | 37,318 | 51,802 | 90,672 |
| Cash and cash equivalents at end of period | $224,462 | $37,318 | $51,802 |
| Supplemental disclosure of cash flow information | |||
| Interest paid | $1,096 | $1,064 | $73 |
| Supplemental non-cash disclosures | |||
| Warrants issued in connection with debt facility | $— | $— | $294 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.